Invega sustenna and Urinary incontinence for Women aged 60+ (a phase IV clinical study of FDA data)

Summary:

Urinary incontinence is found for women aged 60+ who take Invega sustenna (paliperidone palmitate). This study is created by eHealthMe based on reports of 552 women aged 60+ from the FDA, and is updated regularly. The information that eHealthMe analyzes includes:

Time on Invega sustenna when people have Urinary incontinence
Top conditions
Top co-used drugs
Top other side effects

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 01, 2026

552 women aged 60+ reported to have side effects when taking Invega sustenna.
Among them, 12 people (2.17%) have Urinary incontinence

What is Invega sustenna?

Invega sustenna has active ingredients of paliperidone palmitate. It is often used in schizophrenia. eHealthMe is studying from 23,232 Invega sustenna users. Check the latest studies of Invega sustenna.

What is Urinary incontinence?

Urinary incontinence (inability to control the flow of urine and involuntary urination) is found to be associated with 1,632 drugs and 2,518 conditions by eHealthMe. Check the latest studies of Urinary incontinence.

Number of reports submitted per year:

Could Invega sustenna cause Urinary incontinence in women aged 60+?

Time on Invega sustenna when people have Urinary incontinence *

Severity of Urinary incontinence

n/a

How people recovered from Urinary incontinence

n/a

Top conditions involved for these people *:

You may use this to check any potential undetected conditions.

Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 16.67%
Bipolar Disorder (mood disorder): 2 people, 16.67%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 1 person, 8.33%
Stress And Anxiety: 1 person, 8.33%
Schizophrenia, Paranoid Type (delusions and auditory hallucinations but relatively normal intellectual functioning and expression of affect): 1 person, 8.33%
Pain: 1 person, 8.33%
Insomnia (sleeplessness): 1 person, 8.33%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 8.33%
Diarrhea: 1 person, 8.33%
Depression: 1 person, 8.33%

Top co-used drugs for these people *:

You may use this to check any potential interacting drugs.

Invega: 3 people, 25.00%
Albuterol: 2 people, 16.67%
Ipratropium Bromide: 2 people, 16.67%
Combivent: 2 people, 16.67%
Aspirin: 1 person, 8.33%
Celebrex: 1 person, 8.33%
Colestipol Hydrochloride: 1 person, 8.33%
Femhrt: 1 person, 8.33%
Humira: 1 person, 8.33%
Ingrezza: 1 person, 8.33%

Top other side effects for these people *:

You may use this to check any potential undetected side effects.

Tremor (trembling or shaking movements in one or more parts of your body): 4 people, 33.33%
Weight Increased: 3 people, 25.00%
Speech Disorder: 3 people, 25.00%
High Blood Pressure: 3 people, 25.00%
Weakness: 3 people, 25.00%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 2 people, 16.67%
Appetite - Increased (increased appetite is when you want to eat much more often or in larger quantities than your body requires): 2 people, 16.67%
Confusional State: 2 people, 16.67%
Drug Ineffective: 2 people, 16.67%
Hospitalisation: 2 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Invega sustenna and have Urinary incontinence?

- Check whether Urinary incontinence is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies:

Invega sustenna and Urinary incontinence

How the study uses the data?

The study is based on (applicable) gender, age, paliperidone palmitate (the active ingredients of Invega sustenna) and Invega sustenna (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.